top of page

Kidney Disease Enters the Precision Medicine Revolution [STAT Summit 2026 Review #31]

Nov 10
5 min read

Report 31. Kidney Disease Enters the Precision Medicine Revolution

Part I. English Version


1. Event / Date & Time

Event: Kidney Disease Enters the Precision Medicine Revolution | Sponsored by Biogen

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 2:20 PM EDT


2. Participants

Speakers

- Jamil R. Azzi, M.D., Ph.D. — Director, Kidney and Pancreas Transplantation Program, Brigham and Women’s Hospital; Associate Professor, Harvard Medical School

- Janine Gaiha-Rohrbach — Head of Global Medical Immunology, Biogen

- Mark Lim, Ph.D. — Vice President, Research, Discovery and Innovation, American Society of Nephrology’s Alliance for Kidney Health


Moderator

- Jesse McQuarters — Branded Content Editor, STAT


3. Summary

Biology-Driven Kidney Care: Advances in immunology, genomics and biomarkers are moving nephrology beyond broad symptom-based classifications toward molecularly defined disease mechanisms.


Targeted Treatment Development: The panel discussed heterogeneous causes of kidney injury and rejection that could justify more precise therapeutic selection.


Meaningful Patient Outcomes: Delaying dialysis, transplant or disease progression was emphasized as a clinically important benefit even without a cure.


4. Main Discussion

From Pathology to Molecular Drivers

Gaiha-Rohrbach explained that nephrology historically relied on similar nonspecific treatments across distinct diseases. Molecular profiling, immunology and biomarker research increasingly reveal biological drivers that may require different interventions. In antibody-mediated transplant rejection, she noted that mechanisms can include antibody-independent processes as well as antibody-related injury.

The panel contrasted kidney care’s traditional reliance on clinical manifestations, biopsy findings and creatinine with newer molecular explanations of disease. Azzi described creatinine as a relatively late indicator of injury and argued that treatment based on visible damage can miss earlier biological processes. Biogen’s medical representative discussed immune-mediated kidney diseases in which different molecular mechanisms may underlie what appears clinically to be the same syndrome. For antibody-mediated rejection, for example, the discussion distinguished antibody-dependent activity from potentially relevant antibody-independent processes. The proposed precision-medicine shift is to identify biological drivers and intervene earlier instead of applying the same non-specific treatment to all patients. This remains a direction for research and development, not an assertion that every proposed biomarker is ready for routine use.

Speakers described a shift away from classifying kidney disease mainly by clinical presentation and tissue pathology. Janine Gaiha-Rohrbach argued that longstanding reliance on nonspecific treatments can obscure very different biological drivers and leave some patients progressing despite care. She highlighted advances in immunology, genomics and molecular profiles that may help identify mechanisms and treatment targets. Antibody-mediated rejection following kidney transplantation illustrated the issue: according to the panel, research now recognizes mechanisms that are not fully explained by antibodies alone. The implication is that a diagnosis may need several molecular subtypes before a targeted intervention can be matched appropriately.


The Oncology Analogy

Lim compared nephrology’s current transition with oncology’s shift over the past two decades from treating broad cancer categories to understanding molecular subtypes. He argued that integrating genomics, proteomics and data could reveal treatment-relevant distinctions within kidney diseases. The comparison was used as a strategic analogy rather than evidence that nephrology has already matched oncology’s progress.

Azzi compared nephrology’s emerging moment with an earlier stage of oncology, when cancer categories were often defined more by the organ involved than molecular drivers. The speakers described advances in immunology, genomics, transcriptomics and related “omics” methods as opportunities to divide broad diagnostic labels into more actionable subgroups. Researchers can potentially connect a molecular signature with prognosis, a therapeutic target and a measurable response, but establishing those connections requires carefully collected clinical samples and prospective evaluation. A biomarker useful for explaining disease is not necessarily validated for selecting a treatment. The panel treated the pathway from molecular characterization through trial design and regulatory evidence as an important part of the remaining translational challenge.

Jamil Azzi emphasized the potential of urine-based biomarkers because urine can carry signals from the kidney directly, making it an appealing source of information about organ injury and immune activity. He contrasted molecular approaches with creatinine, which he characterized as a relatively late indicator of injury. Molecular signatures might support earlier detection and potentially reduce dependence on invasive biopsy, although clinical validation would be required for each intended use. The discussion was careful not to present a single urine test as universally replacing established pathology. Diagnostic assays need demonstrated accuracy, defined patient populations and evidence that acting on results improves care.


Patient Priorities: Time Before Dialysis

Lim recounted a young patient who said postponing kidney failure, dialysis or transplantation by ten years would allow time to establish a family and career. The example showed why patient-valued outcomes should shape target selection and trial endpoints alongside laboratory measures.

The patient perspective supplied a different definition of meaningful success. One panelist recalled a young person with kidney disease who hoped that a treatment could delay dialysis or transplantation by ten years, long enough to establish a family and career. This illustrates how a relatively modest-looking change in a laboratory measure may have major consequences for daily life and life planning. Conversely, a statistically measurable biological response may not capture what patients value most. The discussion therefore connected patient engagement to endpoint selection, risk–benefit judgments and research priorities, not merely to education at the time a product is marketed. The ten-year example was an individual patient’s aspiration rather than a demonstrated effect of an existing medicine.

The oncology comparison highlighted how biomarkers can move from academic discovery to clinical decision-making. The panel referred to the way molecular profiling transformed cancer classification and drug development over the past two decades, while noting that nephrology has different anatomy, biology and outcome measures. Mark Lim also discussed collaboration among professional societies, regulators, industry and patients to clarify what evidence is needed. A companion diagnostic is useful only if there is a validated intervention linked to the result or a meaningful prognostic decision. The analogy therefore offered a development path to examine, not proof that kidney disease will reproduce oncology’s exact therapeutic trajectory.


Diagnostics, Biomarkers and Collaboration

The panel anticipated broader use of integrated omics, molecular diagnostics and longitudinal information to characterize disease and monitor response. Developing therapies around biologically meaningful patient groups would require partnerships among nephrologists, industry researchers and patient communities.

Speakers presented coordination across academic nephrology, biopharmaceutical developers, professional societies, regulators and patients as necessary for a precision approach. Standardized definitions and usable trial endpoints help researchers compare results across institutions and molecular subgroups. The conversation referenced interaction between the FDA and the kidney professional community over what outcomes should matter to patients, illustrating how clinical priorities and regulatory needs may develop jointly. Looking ahead, the panel envisioned integrating molecular datasets with patient histories to recognize disease trajectories earlier and evaluate targeted medicines. This vision remains conditional on reproducible assays, accessible diagnostics, meaningful outcomes and sufficient trial populations for relatively uncommon disease subsets.

Patient priorities helped frame what precision medicine ought to achieve. Azzi recalled a patient who said that delaying the need for dialysis or transplantation by ten years could change the possibility of having and raising children. This example turns an abstract endpoint such as renal function decline into a life-course outcome that matters to a person. Trials still require reliable clinical measures, but patient perspectives can inform acceptable risk, the timing of intervention and outcomes beyond laboratory values. Longer-term progress will depend on integrating biobanks, molecular research, companion tests, targeted medicines and real-world follow-up into a coherent development pathway.


5. Insights

Mechanism-Based R&D: Kidney drug development may advance through molecular subtyping and validated biomarkers rather than uniform treatment of heterogeneous disorders.


Implications for South Korea: Korea could consider integrated nephrology biobanks, molecular profiling and clinically meaningful endpoints in precision kidney-disease research.


Translational Networks: Collaboration among hospitals, diagnostic developers, biotechnology firms and patient groups may accelerate targeted interventions.



Comments


© 2026 KHIDI USA ALL RIGHT RESERVED

bottom of page